Akeso (FRA:4RY) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4RY Akeso Inc FRA:4RY
51 GF Score
Price €11.27
GF Value €18.80
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Akeso Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:4RY
51GF Score
Akeso Inc FRA:4RY
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Akeso (FRA:4RY) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of €11.27 is trading 40.1% below its estimated GF Value™ of €18.80. GuruFocus considers Akeso to be Possible Value Trap.

Key valuation signals for FRA:4RY:

  • Interest Received:
  • GF Value™: €18.80 vs. price of €11.27 (40.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akeso Business Description

Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
51GF Score

Get the complete analysis for FRA:4RY

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.27
Price
€18.80
GF Value